ALBIREO PHARMA, INC. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2015 to Q3 2022

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Albireo Pharma, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2015 to Q3 2022.
  • Albireo Pharma, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2022 was $2.03M, a 55.2% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2022 $2.03M +$722K +55.2% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $1.85M Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $1.28M Mar 31, 2022 10-Q 2022-05-16
Q4 2021 $3.27M +$3.27M Dec 31, 2021 10-Q 2022-11-08
Q3 2021 $1.31M Sep 30, 2021 10-Q 2021-11-04
Q4 2020 $0 Dec 31, 2020 10-K 2022-03-01
Q3 2017 $11K Sep 30, 2017 10-Q 2017-11-14
Q1 2017 $1K* Mar 31, 2017 10-Q 2017-05-11
Q4 2016 $26K -$1.25M -98% Dec 31, 2016 10-Q 2017-11-14
Q4 2015 $1.27M Dec 31, 2015 10-K 2017-03-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.